

The Honorable

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON AT SEATTLE

MICHELLE BRUTO DA COSTA,  
Individually and as personal representative of  
the Estate of MARK BRUTO DA COSTA,  
deceased,

Plaintiffs,

v.

OLYMPUS AMERICA INC., OLYMPUS  
CORPORATION, OLYMPUS MEDICAL  
SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS,  
OLYMPUS SURGICAL TECHNOLOGIES  
AMERICA, AIZU OLYMPUS CO. LTD,  
AOMORI OLYMPUS CO. LTD.,  
SHIRAKAWA OLYMPUS CO. LTD.,

Defendants.

No.

**COMPLAINT**

JURY TRIAL DEMANDED

Plaintiffs Michelle Bruto Da Costa ("Plaintiff"), individually and on behalf of the Estate of Mark Bruto Da Costa ("Decedent"), by and through the undersigned counsel, bring this Complaint for damages against Olympus America Inc., Olympus Corporation, Olympus Medical Systems Corp., Olympus Corporation of the Americas, Olympus Surgical Technologies America, Aizu Olympus Co. Ltd, Aomori Olympus Co. Ltd., and Shirakawa Olympus Co. Ltd.,

(collectively “Defendants or Olympus Defendants”). In support thereof, Plaintiffs state the following:

**I. PRELIMINARY STATEMENT**

1. This is a medical device tort action brought on behalf of the above-named Plaintiffs arising out of the failure of Defendants’ endoscope, the Olympus TJF-Q190V duodenoscope (“Endoscope Device”) and Defendants’ failure to warn.

2. As a direct and proximate result of Defendants’ misconduct, Decedent died. This action seeks compensatory and punitive damages, costs incurred and to be incurred by Decedent and the Estate, and any other damages that the Court or jury may deem appropriate, arising from the intentional, malicious, knowing, reckless, and/or negligent acts and/or omissions of Defendants in connection with the Endoscope Device.

3. Plaintiffs respectfully seek damages in excess of \$75,000 for all damages to which Plaintiffs may be legally entitled.

**II. PARTIES**

4. Plaintiff, Michelle Bruto Da Costa, is a citizen of the United States of America, a current resident of Woodway, Washington, and the duly appointed, qualified, and acting executor of the Estate of Decedent Mark Bruto Da Costa.

5. Plaintiff, Michelle Bruto Da Costa, was born on July 20, 1980, and at all relevant times a citizen and resident of Snohomish County in the city of Woodway, Washington and the United States.

6. Plaintiff, Michelle Bruto Da Costa married Decedent Mark Bruto Da Costa on July 26, 2003.

7. At all relevant times, Plaintiff Michelle Bruto Da Costa was married to Decedent, Mark Bruto Da Costa.

1           8.       Decedent, Mark Bruto Da Costa, was born on September 17, 1978, and at all  
2       revenue times was a citizen and resident of Snohomish County in the city of Woodway,  
3       Washington and the United States.

4           9.       Decedent acquired vancomycin-resistant Enterococcus (“VRE”) from the  
5       Endoscope Device which was the proximate cause of Decedent’s death.

6           10.      Decedent, Mark Bruto Da Costa died on June 28, 2023.

7           11.      Plaintiff and Decedent are referred collectively in this Complaint as Plaintiffs.

8           12.      Defendant Olympus America Inc. is and, at all times relevant to this action, has  
9       been a United States corporation that is incorporated under the laws of the State of New York.  
10      Olympus America Inc. has its principal place of business at 3500 Corporate Parkway, Center  
11      Valley, PA 18034.

12           13.      Olympus Corporation of the Americas is and, at all times relevant to this action,  
13      has been a United States corporation that is incorporated under the laws of the State of New  
14      York. Olympus Corporation of the Americas has its principal place of business at 3500  
15      Corporate Parkway, Center Valley, PA 18034.

16           14.      Olympus Surgical Technologies America is and, at all times relevant to this  
17      action, has been a subsidiary of Olympus Corporation of the Americas. Olympus Surgical  
18      Technologies America has its headquarters at 800 West Park Drive, Westborough,  
19      Massachusetts, 01581.

20           15.      Defendant Olympus Medical Systems Corp. is and, at all times relevant to this  
21      action, has been a Japanese Corporation with its principal place of business at 2951 Ishikawa-  
22      maschi, Hachioji-shi, Tokyo 192-8507, Japan.

1           16.     Aizu Olympus Co. is and, at all times relevant to this action, has been a Japanese  
2 Corporation having its principal place of business at 3-1 Nishi-Shinjuku 2-Chome Shinjuku-Ku  
3 Tokyo 163-0914 Japan.

4           17.     Aomori Olympus Co. Ltd is and, at all times relevant to this action, has been a  
5 Japanese Corporation having its principal place of business at 2-248-1 Okkonoki, Kuroishi-shi,  
6 Aomori 036-0357, Japan.

7           18.     Shirakawa Olympus Co. Ltd is and, at all times relevant to this action, has been a  
8 Japanese Corporation having its principal place of business at 3-1 Oaza-Odakura-Aza-  
9 Okamiyama, Nishigo-mura, Nishishirakawa-gun, Fukushima 961-8061, Japan.

10           19.     Defendant Olympus Corporation is and, at all times relevant to this action, has  
11 been a Japanese corporation having a principal place of business at 2951 Ishikawa-maschi,  
12 Hachioji-shi, Tokyo 192-8507, Japan.

13           20.     Defendant Olympus Corporation is and, at all times relevant to this action, has  
14 been the parent company of Olympus America Inc., Olympus Medical Systems Corp., Olympus  
15 Corporation of the Americas, Olympus Surgical Technologies America, Aizu Olympus Co. Ltd,  
16 Aomori Olympus Co. Ltd., and Shirakawa Olympus Co. Ltd.

17           21.     Defendant Olympus Corporation is and, at all times relevant to this action, has  
18 exercised and exercises dominion and control over Olympus America Inc., Olympus Medical  
19 Systems Corp., Olympus Corporation of the Americas, Olympus Surgical Technologies  
20 America, Aizu Olympus Co. Ltd, Aomori Olympus Co. Ltd., and Shirakawa Olympus Co. Ltd.

21           22.     Defendant Olympus Corporation was at all material times responsible for the  
22 actions of Olympus America Inc., Olympus Medical Systems Corp., Olympus Corporation of the  
23 Americas, Olympus Surgical Technologies America, Aizu Olympus Co. Ltd, Aomori Olympus  
24  
25  
26

1 Co. Ltd., and Shirakawa Olympus Co. Ltd. It exercised control over these entities specific to the  
2 oversight and compliance with applicable safety standards regarding Endoscope Devices sold  
3 throughout the states and territories of the United States.<sup>1</sup> In such capacity, Defendant Olympus  
4 Corporation committed or allowed to be committed tortious and wrongful acts, including the  
5 violation of numerous safety standards relating to manufacturing, quality assurance/control, and  
6 conformance with design and manufacturing specifications.

7  
8 23. Each of the Olympus Defendants was the agent and employee of the other  
9 Olympus Defendants and, in doing the things alleged, was acting with the court and scope of  
10 such agency and employment with the other Olympus Defendants' actual and implied  
11 permission, consent, authorization, and approval.

12  
13 24. The Olympus Defendants, in collaboration amongst themselves, designed, tested,  
14 researched, and developed the Endoscope Device at issue in this litigation.

15  
16 25. As part of their business and at all relevant times, the Olympus Defendants have  
17 been involved in the design, research, manufacture, testing, advertisement, promotion,  
18 marketing, sale, and distribution of the Endoscope Devices.

19  
20 26. The Olympus Defendants, in collaboration amongst themselves, designed and  
21 developed the Endoscope Devices.

22  
23 27. The Olympus Defendants, in collaboration amongst themselves, manufacture and  
24 market the Endoscope Devices in the United States.

25  
26 28. The Olympus Defendants have transacted and conducted business related to the  
Endoscope Devices in each of the states and territories of the United States.

---

<sup>1</sup> See Olympus Corporation; First Quarter Financial Results FY2026, Presentation Materials at 5-10, *available at* <https://www.olympus-global.com/ir/data/brief/2026.html?page=ir> (emphasizing its leadership in responding to FDA compliance and regulatory issues and guiding new innovations and product launches).

1           29.     The Olympus Defendants have expected or should have expected their acts to  
2 have consequence within each of the states and territories of the United States, and derived  
3 substantial revenue from interstate commerce in each of the states and territories of the United  
4 States related to the Endoscope Devices.

5           30.     The Olympus Defendants, in collaboration amongst themselves, have, at all  
6 relevant times, been involved throughout all states and territories in the United States in the  
7 research, development, testing, manufacture, production, marketing, promotion and/or sale of  
8 medical devices, including the Endoscope Device in this litigation. The Olympus Defendants  
9 have derived substantial revenue related to Endoscope Devices from their business throughout  
10 each of the states and territories of the United States. All acts and omissions of the Olympus  
11 Defendants as described herein, including but not limited to, those resulting in the design,  
12 manufacture, marketing, labeling, distribution, sale and placement of its Endoscope Device at  
13 issue in the instant suit, were done by their agents, servants, employees and/or owners, acting in  
14 the course and scope of their representative agencies, services, employments and/or ownership.  
15 At all times material hereto, the Olympus Defendants did business in the United States, and  
16 specifically, engaged with regulatory authorities and the medical community within the United  
17 States and Washington.

18           31.     The Olympus Defendants control the largest U.S. market share of Endoscope  
19 Devices and participate in the manufacture and distribution of the Endoscope Devices throughout  
20 all states and territories of the United States.

21           32.     The Olympus Defendants are individually and jointly and severally liable to  
22 Plaintiffs for damages Plaintiffs suffered arising from the design, manufacture, marketing,  
23 labeling, improper/inadequate warnings, distribution, sale, and placement of Defendants’  
24  
25  
26

1 Endoscope Devices, effectuated directly and indirectly through Defendants' agents, servants,  
2 employees and/or owners, all acting within the course and scope of their representative agencies,  
3 services, employments and/or ownership.

4 33. The Olympus Defendants are also vicariously liable for the acts and omissions of  
5 their employees and/or agents who were at all material times acting on Defendants' behalf and  
6 within the scope of their employment or agency.  
7

### 8 III. JURISDICTION AND VENUE

9 34. At all relevant times, during their lives, Plaintiffs were citizens of Snohomish  
10 County in the city of Woodway, Washington and the United States.

11 35. Decedent's endoscopic procedure using Defendants' product, which to a  
12 reasonable medical degree of scientific certainty caused Decedent's infection and eventual death,  
13 was performed in Seattle, Washington, within the Western District of Washington.  
14

15 36. This Court has subject-matter jurisdiction over this action pursuant to 28 U.S.C. §  
16 1332(a) based on complete diversity of citizenship between Plaintiffs and all Defendants. The  
17 amount in controversy exceeds \$75,000.00.

18 37. This Court has personal jurisdiction over Defendants because at all times relevant  
19 to this lawsuit, Defendants transacted business within the State of Washington and contracted to  
20 sell and supply their Endoscope Devices in this State. Defendants employ sales representatives in  
21 this state to sell their products throughout the State, including the Endoscope Device used in  
22 Decedent in 2023 at the University of Washington Medical Center in Seattle, Washington.  
23 Defendants' tortious acts and omissions in the State of Washington caused injury to Plaintiffs.  
24

25 38. Defendants have purposefully engaged in the State of Washington in the business  
26 of developing, manufacturing, publishing information, marketing, distributing, promoting and/or  
selling, either directly or indirectly, through third parties or other related entities, medical devices

1 including the Endoscope Device at issue, for which they derived significant and regular income.  
 2 Defendants intended and reasonably expected that that their defective Endoscope Devices,  
 3 including the TJF-Q190V duodenoscope, would be sold and used in the Western District of  
 4 Washington and could cause injury in Western District of Washington.

5 39. Defendants have also purposely availed themselves to the privilege of conducting  
 6 business within this State and have the requisite minimum contacts with this State such that the  
 7 maintenance of this suit does not offend traditional notions of fair play and substantial justice.  
 8 Defendants should reasonably anticipate being hauled into Court here.

9 40. Consistent with the Due Process Clause of the Fifth and Fourteenth Amendments,  
 10 Defendants are subject to personal jurisdiction in this District.

11 41. A substantial part of the events and omissions giving rise to Plaintiffs' causes of  
 12 action occurred in this District.

13 42. Venue is proper in this Court pursuant to 28 U.S.C. §1391(a).

#### 14 **IV. FACTS COMMON TO ALL COUNTS**

15 43. On or about June 12, 2023, Decedent underwent an endoscopic procedure,  
 16 specifically an endoscopic retrograde cholangiopancreatography ("ERCP") performed by Dr.  
 17 Anand Singla at University of Washington Medical Center ("UWMC") in Seattle, Washington.  
 18 An Olympus TJF-Q190V duodenoscope device was used to perform the endoscopic procedure.

19 44. Defendants manufactured, sold, and/or distributed the TJF-Q190V to be used in  
 20 endoscopic procedures like the procedure performed on Decedent.

21 45. On or about June 16, 2023, within 4 days of exposure, Decedent presented to  
 22 Shae Medical Center for paracentesis. Blood cultures were obtained showing gram-positive  
 23 cocci.

1           46.     On June 18, 2023, Infectious Disease specialist, Dr. John Burge noted Decedent  
2     had “taken a definitive turn for the worse with significant weight loss and persistent leukocytosis  
3     and worsening hyperbilirubinemia.”

4           47.     Despite varied effort and treatment, the VRE could not be eradicated from within  
5     Decedent.

6           48.     VRE was not present on any of Decedent’s extensive bloodwork until after the  
7     June 12, 2023, ERCP procedure using Defendants’ Olympus TJF-Q190V.

8           49.     The Endoscope Device has been repeatedly implicated in outbreaks of multidrug-  
9     resistant organisms, including VRE.

10          50.     Decedent died on June 28, 2023, due to organ failure and septic shock  
11     proximately caused the VRE introduced by Endoscope Device.

12          51.     Defendants were responsible for the research, design, development, testing,  
13     manufacture, production, marketing, promotion, distribution and sale of the Endoscope Device,  
14     including providing warnings and instructions concerning their product.

15          52.     Among the intended purposes for which Defendants designed, manufactured and  
16     sold the Endoscope Device was its use by doctors for endoscopic procedures. That was the  
17     purpose for which the Endoscope Device was used on Decedent.

18          53.     Defendants represented to Decedent and Decedent’s physician that the Endoscope  
19     Device was safe and effective for endoscopic procedures.

20     **A.     FDA 510(k) CLEARANCE PROCESS**

21          54.     The “510(k) clearance process” of the U.S. Food & Drug Administration (FDA)  
22     refers to Section 510(k) of the 1976 Medical Device Amendments to the Federal Food, Drug and  
23     Cosmetic Act (MDA). Under this process, medical device manufacturers are only required to  
24     notify the FDA at least 90 days before they market a device claimed to be “substantially  
25

1 equivalent” to a device the FDA had approved for sale before 1976 (when the MDA was  
2 enacted).

3 55. No clinical testing or clinical study is required to gain FDA approval under this  
4 process. Instead, a given device was supposed to demonstrate substantial equivalence to a  
5 predicate medical device.  
6

7 56. Subsequent amendments to the MDA allowed for 510(k) clearance of products  
8 deemed “substantially equivalent” to post-MDA, 510(k)-cleared devices.

9 57. Through this domino effect, devices deemed “substantially equivalent” to devices  
10 previously deemed “substantially equivalent” to devices the FDA had approved for sale pre-1976  
11 could be sold to patients in a matter of 90 days—without any clinical testing.  
12

13 58. Therefore, clearance for sale under the 510(k) process does not equate to FDA  
14 approval of the cleared medical device.

15 59. At the request of the FDA in 2012, the National Institute of Health (NIH)  
16 conducted a thorough review of the 510(k) process, reaching the following major conclusion:

17 The 510(k) clearance process is not intended to evaluate the safety and  
18 effectiveness of medical devices with some exceptions. The 510(k) process  
19 cannot be transformed into a pre-market evaluation of safety and effectiveness so  
20 long as the standard for clearance is substantial equivalence to any previously  
21 cleared device.

22 60. The NIH explained: “The assessment of substantial equivalence does not require  
23 an independent demonstration that the new device provides a ‘reasonable assurance of safety and  
24 effectiveness.’” Further, the NIH even pointed out that the classification of predicate devices  
25 approved for sale prior to 1976 “did not include any evaluation of the safety and effectiveness of  
26 individual medical devices . . . Thus it is common for devices to be cleared through the 510(k)  
program by being found substantially equivalent to devices that were never individually

1 evaluated for safety and effectiveness, either through the original device classification program  
2 or through the 510(k) process.”

3 61. Defendants sought and obtained FDA clearance to market their Endoscopic  
4 Devices under Section 510(k) of the Medical Device Amendment to the Food, Drug and  
5 Cosmetics Act. Section 510(k) provides for marketing of a medical device if the device is  
6 deemed “substantially equivalent” to other predicate devices marketed prior to May 28, 1976.  
7 The 510(k) process is not a formal review for safety or efficacy. No clinical testing or clinical  
8 study is required to gain FDA clearance under this process. Upon information and belief, no  
9 formal review for safety or efficacy was ever conducted for the Endoscopic Devices.  
10

#### 11 **B. DEFENDANTS’ ENDOSCOPE DEVICE: DEFECTS & RISKS**


12 62. In 2017, there were more than 20 million endoscope procedures in the U.S.<sup>2</sup> By  
13 2019, that number had grown to 22 million.<sup>3</sup>  
14

15 63. Defendants’ Endoscope Device is a thin, tube-like instrument used to look at  
16 tissues inside the body. It has a light and lens for viewing, a channel for inserting tools to remove  
17 tissue, a forceps elevator, a v-groove for guidewires, and an air/water nozzle. The insertion tube  
18 contains long, narrow working channels. An illustrative diagram of an Olympus endoscope is  
19 shown below<sup>4</sup>:  
20  
21  
22  
23

24 <sup>2</sup> Wang P., Xu T., Ngamruengphong S., Makary M.A., Kalloo A., Hutfless S. Rates of infection after colonoscopy  
25 and esophagogastroduodenoscopy in ambulatory surgery centres in the USA. Gut. 2018;67:1626–1636. doi:  
10.1136/gutjnl-2017-315308.

26 <sup>3</sup> Peery A., Crockett S., Murphy C., Jensen E., Kim H., Egberg, M. Lund J., Moon A., Pate V., Barnes E., Schlusser  
C., Baron T., Shaheen N., Sandler R. Burden and Costs of Gastrointestinal, Liver, and Pancreatic Diseases in the  
United States: Update 2021. Gastroenterology. 2021 Oct.

<sup>4</sup> <https://www.olympus-global.com/technology/museum/fiber.html?page=technology> (last visited June 5, 2026).



64. Defendants' Endoscope Devices are designed and intended for repeated and recurrent use in multiple medical procedures involving different patients. After each use, Defendants' Endoscope Devices necessarily require cleaning and disinfecting (known as "reprocessing"), before they can be safely used on a new patient.

65. Defendants knew or should have known that their Endoscope Devices would be used in multiple procedures involving many different patients and have an obligation to develop and validate a safe and effective reprocessing protocol to be included in the Devices' packaging and labeling instructions such as the Instructions for Use (IFU), and/or Reprocessing Manual, and/or Operation Manual ("Product Labeling").

66. The Product Labeling must provide sufficient instructions on how to prepare the Endoscopic Devices for the safe use on the next patient. Pursuant to federal law, the manufacturer of a medical device is required to maintain a Device Master Record and/or design history file as appropriate, which must include documentation of tests that were performed to demonstrate that the processing instructions are complete, understandable, and can reasonably be executed by the user in a safe and effective manner. The Device master Record must comply with the 21 C.F.R. § 820.181 and the design history file must comply with 21 C.F.R. § 820.30(j).

1 The manufacturer must ensure that the validated reprocessing protocol is disseminated to  
2 medical providers.


3 67. Defendants' Endoscope Device is defective because, among other defects,  
4 medical providers were not able to safely and effectively sanitize and clean the Endoscope  
5 Device even if the providers strictly complied with Defendants' reprocessing instructions  
6 contained in the Product Labeling.  
7

8 68. As a direct result of Defendants' failure to develop and validate effective  
9 reprocessing protocol for their Endoscope Devices, multiple patients, like Decedent can be  
10 exposed to contaminated Endoscope Devices.

11 69. The medical providers who are the end-users of Defendants' Endoscope Devices  
12 rely on the manufacturer Defendants to provide an effective and validated reprocessing protocol.  
13 Providers are not aware that Defendants' protocols are not effective in removing all residual  
14 bodily fluids and organic debris from the Endoscope Device after use, which can become trapped  
15 in tiny crevices near the tip of the device and within the long narrow channels of the device,  
16 which contain microbial contamination thereby exposing patients who undergo a procedure with  
17 a contaminated device to health risks, including severe infection, sepsis, organ failure, and death,  
18 among other injuries.  
19

20 70. Not only does the design of the Endoscope Device's complex tip and long, narrow  
21 channels pose a risk of microbial contamination, but the repetitive use—with reprocessing in  
22 between uses—of Defendants' Endoscope Devices results in cracked lenses, degraded channel  
23 linings, and degraded adhesives (*see* exemplar image below). This damage and degradation  
24 allow bacteria to hide from chemical disinfectants, thereby exposing patients who undergo a  
25  
26

procedure with Defendants' Endoscope Device to health risks, including severe infection, sepsis, organ failure, and death, among other injuries.



71. Defendants knew or should have known that available research has demonstrated that, using magnification and borescopes inspection, 100% of endoscopes with narrow channels, like Defendants' Endoscope, showed visible damage, residue, and/or debris, requiring repair 76% of the time.

72. In endoscopes, like Defendants' Endoscope, channel shredding, scratches, and/or defects appear within a few uses, requiring repair. These grooves and defects allow buildup of biofilm and the proliferation of bacteria.

73. Medical providers are not aware that Defendants' Endoscope Devices can become so easily cracked and degraded, making them even more susceptible to bacterial contamination.

1 Upon information and belief, Defendants (through their employees and/or agents) actively  
2 discouraged the use of borescope monitoring (which could detect such cracks in the Endoscope  
3 Device), while responding in writing to any inquiries about borescope monitoring that “Olympus  
4 does not currently have an official stance on the use of borescopes as a tool for visualization of  
5 flexible endoscope channels after manual cleaning.”<sup>5</sup>  
6

7 74. In addition to harboring dangerous microbes, the aforementioned channel  
8 adhesive degradation has been shown to fragment inside patients during endoscopic procedures.  
9 Such shredding and degradation, due to Defendants’ defective endoscope devices and  
10 accompanying protocol, result in the fragmented pieces perforating patients’ bowels, and/or  
11 gastrointestinal tracts, and/or organs, all of which cause catastrophic injuries in patients, like  
12 Decedent, including sepsis, organ failure, and death.  
13

14 75. As recently as July 2025, Defendants’ position on implementing additional  
15 monitoring tools, such as adenosine triphosphate (ATP) testing, microbial culturing, or  
16 borescope monitoring was to refer medical providers to their IFU. To date, Defendants’ Product  
17 Labeling is silent on the use of such monitoring tools.  
18

19 76. Defendants knew or should have known that the Product Labeling accompanying  
20 their Endoscope Devices are inadequate and that human factors were not appropriately  
21 considered in the creation of the Product Labeling and product design.  
22

23 77. Between October of 2017 and October of 2018, the FDA ordered Defendants to  
24 conduct a 522 study on one of Defendants’ endoscopes. A 522 study is a Post-market  
25 Surveillance Study required by the FDA for certain medical devices after a device is already on  
26 the market to gather additional real-world safety and effectiveness data. The FDA can order a

---

<sup>5</sup> <https://medical.olympusamerica.com/sites/default/files/us/files/pdf/Borescope-Use-with-Olympus-Flexible-Endoscopes.pdf> (last visited June 5, 2026).

1 manufacturer to perform one when there are unanswered questions about a device's long-term  
2 performance or risks.

3 78. The specific device studied was a duodenoscope, which, other than the forceps  
4 elevator, shares the same characteristics (insertion tube containing multiple narrow, working  
5 channels, and a distal end), as Defendants' Endoscope.

6  
7 79. The 522 study design discretion was "to demonstrate that representative  
8 reprocessing personnel can follow the recommended reprocessing instructions in the  
9 Duodenoscope labeling and user materials without causing reprocessing errors or failures that  
10 could result in harm to patients."<sup>6</sup> This human factors study consisted of 30 test participants  
11 (including 15 GI nurses and 15 GI techs) to reprocess an Olympus endoscope in accordance with  
12 the manufacturer's reprocessing manual. Of the 73 critical manual cleaning tasks, 45 were not  
13 successfully performed by 27% or more of participants. In another endoscope model (with the  
14 substantially similar narrow channels as Defendants' Endoscope Device), 75 of 111 manual  
15 cleaning tasks were not successful performed.  
16

17 80. The final effectiveness findings of the 522 study were that the user materials (i.e.,  
18 Product Labeling) for the Olympus endoscopes were "not sufficient to consistently ensure user  
19 adherence in the core reprocessing areas: precleaning, manual cleaning, manual high-level  
20 disinfection, rinsing, and storage and disposal."<sup>7</sup>  
21

22 81. As a direct result of Defendants' Endoscope Device's inadequate Product  
23 Labeling, medical professionals are not able to properly clean the Endoscope Device even when  
24 strictly adhering to Defendants' reprocessing protocol contained in the Product Labeling.  
25

---

26 <sup>6</sup> FDA. Olympus 522 Post Market Surveillance Studies-Human factors study.  
[https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm?t\\_id=354&c\\_id=3692](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm?t_id=354&c_id=3692) (last visited June 5,  
2026).

<sup>7</sup> *Id.*

1           82. As a direct result of Defendants' Endoscope Device's inadequate Product  
2 Labeling, soil retained inside the nonvisible channels of Defendants' Endoscope prevents  
3 disinfectants from making full contact and can shield microbes. If the soil is organic, it doubles  
4 as a food source, allowing bacterial contaminants to multiply exponentially. When a sterile tool  
5 or water is pushed across this food source and inserted into the organs of the next patient, the  
6 microbes transfer as well. Defendants knew or should have known that allowing moisture to  
7 remain inside the unseen interior channels of Defendants' Endoscope Device can harbor enough  
8 bacteria or viral load to become catastrophic for patients, like Decedent. If even small amounts  
9 of moisture remain in Defendants' Endoscope Device, bacteria can proliferate at alarming rates.  
10

11           83. Defendants knew or should have known that moisture trapped inside the channels  
12 of Defendants' Endoscope Device cannot be observed by reprocessors and/or medical providers,  
13 yet Defendants fail to mandate (or even recommend) drying indicators to test for residual fluid  
14 before storage.  
15

16           84. In a 2022 post-market surveillance study ordered by FDA, Defendants could only  
17 demonstrate 34.8% of Defendants' sampled endoscopes contained no contamination.  
18

19           85. Defendants knew or should have known that their failure to instruct medical  
20 providers to conduct borescope inspections, dryness indicator tests, adenosine triphosphate  
21 (ATP) testing, and/or microbial culturing would expose multiple patients, like Decedent, to  
22 contaminated Endoscope Devices.

23           86. The level of processing Defendants instruct medical providers to perform as part  
24 of the reprocessing protocol contained in their Product Labeling is also inadequate. The  
25 Spaulding Classification System categorizes three levels of processing: low-level disinfection,  
26 high-level disinfection ("HLD"), and sterilization. Scientific literature reports that real-world

1 testing has detected microbes on 6%–72% of reprocessed (and clinically used) endoscopes after  
2 HLD. Although the scientific literature advocates for sterilization of endoscopes instead of HLD,  
3 Defendants’ Product Labeling for the Endoscope Device calls for HLD and implicitly advises  
4 against sterilization. Defendants knew or should have known that (1) sterilization kills all  
5 microbes, including spores, whereas HLD at best kills vegetative microbes and may allow spores  
6 to survive; (2) sterilization shows roughly double the reduction in microbial bioburden than  
7 HLD; (3) sterilization would give proper consideration to the expected human factor  
8 deficiencies, which have been shown to exist as a direct result of Defendants’ inadequate and  
9 defective Product Labeling. Upon information and belief, in accordance with Defendants’  
10 Product Labeling, the majority of facilities in the United States utilize HLD instead of  
11 sterilization on Defendants’ endoscope devices, including the Endoscope Device at issue.  
12

13 **C. DEFENDANTS’ ACTS & OMISSIONS REGARDING THEIR DEFECTIVE**  
14 **DEVICE**

15 87. At all material times, Defendants were responsible for designing, manufacturing,  
16 producing, testing, studying, inspecting, labeling, marketing, advertising, selling, and promoting,  
17 and distributing their Endoscope Devices, and providing warnings/information about the  
18 Endoscope Devices.  
19

20 88. Defendants’ Endoscope Devices were defectively designed and manufactured;  
21 and were also defective as marketed due to inadequate warnings, instructions, labeling and/or  
22 inadequate testing, despite Defendants’ knowledge of the Endoscopes Devices’ lack of safety  
23 and inadequate reprocessing protocol.  
24

25 89. Defendants had independent obligations to know and timely and adequately  
26 disclose scientific and medical information about their Endoscope Devices and inadequate

1 reprocessing protocol; and to warn of their risks and side effects as soon as each Defendant was  
2 aware of them. Defendants did not do so.

3 90. Defendants also knew or should have known that their Endoscope Devices and  
4 accompanying inadequate reprocessing protocol unreasonably exposed patients, like Decedent,  
5 to the risk of serious harm, while conferring no benefit over available feasible and safer  
6 alternatives that did not present the same risks and adverse effects.

7 91. Defendants made claims regarding the benefits of using the Endoscope Devices  
8 but minimized or omitted their risks and adverse effects. Although Defendants knew or should  
9 have known that their claims were false and misleading, they failed to adequately disclose the  
10 true health consequences and the true risks and adverse effects of the Endoscope Devices.

11 92. At all material times, Defendants failed to provide sufficient warnings and  
12 instructions that would have put Decedent, Decedent's health care providers, and the general  
13 public on notice of the dangers and adverse effects caused by the use of the Endoscope Devices.

14 93. Defendants have marketed and continue to market their Endoscope Devices to  
15 Decedent and Decedent's health care providers as safe, effective and reliable. Defendants also  
16 continue to market their Devices as safer and more effective than available feasible alternatives,  
17 and other competing products. Those alternatives have existed at all material times and have  
18 always presented less frequent and less severe risks and adverse effects than the Endoscope  
19 Devices.

20 94. The risks of the Endoscope Devices' design outweigh any potential benefits  
21 associated with the design. As a result of their defective design and/or manufacture, an  
22 unreasonable risk of severe adverse reactions can occur, including but not limited to infection,  
23 pneumonia, tuberculosis, HIV, sepsis, organ failure, organ perforation, and death.  
24  
25  
26

1           95. Defendants omitted mention of the Endoscope Devices’ risks, dangers, defects,  
2 and disadvantages when they advertised, promoted, marketed, sold and distributed them as safe  
3 to regulatory agencies, health care providers, Decedent, and other consumers. But Defendants  
4 knew or should have known that the Endoscope Devices were not safe for their intended  
5 purposes, and that they would and did cause serious medical problems, including severe and  
6 permanent injuries and damages—and in some cases, catastrophic injuries and death.

7  
8           96. Defendants have underreported complications and injuries resulting after the use  
9 of Endoscope Devices; and have made unfounded representations regarding the efficacy and  
10 safety of the Devices through various means and media.

11           97. Defendant Olympus Medical Systems Corporation pleaded guilty to failing to file  
12 required adverse event reports (“AERs”) involving infection and continuing to sell Defendants’  
13 endoscope devices despite that failure. A former senior executive pleaded guilty to distributing  
14 misbranded medical devices.

15  
16           98. In addition to the criminal prosecution, a July 2022 inspection by the FDA of one  
17 of Defendants’ Japanese factories (Defendant Aizu Olympus Co. Ltd.) found that Defendants’  
18 endoscope devices were “adulterated” and resulted in a Form 483 Warning Letter. The letter  
19 stated that the FDA inspection revealed that the entire device design for endoscopes was not  
20 validated to ensure that devices conform to defined user needs under actual or simulated  
21 conditions. It also found that there were no medical device report (“MDR”) procedures.

22  
23           99. In 2022, the FDA also cited Defendants Aizu Olympus Co. Ltd. and Aomori  
24 Olympus Co. Ltd. for not having procedures in place for dealing with MDRs—one of the most  
25 important post-market surveillance tools available to FDA for monitoring the safety and efficacy  
26 of devices on the market.

1           100. Also in 2022, the FDA cited Defendant Olympus Corporation of the Americas for  
2 having an insufficient/nonexistent MDR system. The FDA found Defendant Olympus  
3 Corporation of the Americas' MDR internal systems were inadequate, staff was not trained, and  
4 there were no procedures for evaluating complaints.

5           101. Further compounding these issues, the FDA inspector for Defendant Aomori  
6 discovered that all of its MDRs were submitted to the FDA to inaccurately reflect Olympus  
7 Medical Systems Corporation or the Olympus Corporation of the Americas as the manufacturing  
8 site. This practice affects the ability of the FDA to detect and remove unsafe devices, such as  
9 Defendants' Endoscope Device.

10           102. Despite the mislabeling of MDRs, the failure of Defendants' facilities to have a  
11 process for MDRs, and the general underreporting of adverse events, there are thousands of  
12 complaints involving Olympus endoscopes on the Manufacturer and User Facility Device  
13 Experience ("MAUDE") database maintained by FDA, many of which report the contraction of  
14 multi-drug resistant organisms (or "super bugs"), sepsis, organ failure, device fragmentation, and  
15 death related to Defendants' endoscope device.

16           103. In addition to the MDRs (both reported and not reported) that should have put  
17 Defendants on notice of their defective Endoscope Devices and inadequate reprocessing  
18 protocol, outbreaks related to endoscopes have been widely reported in scientific literature. For  
19 example, in July 2022 an outbreak was detected in Northern Germany. The outbreak strain was  
20 eventually isolated from a reprocessed, ready-to-use colonoscope. By the end of the outbreak, 32  
21 people had been infected and 6 died.

22           104. In November 2014, 25 cases of a multidrug-resistant bacteria were identified in  
23 Pittsburgh. 76% of the cases had been exposed to the same bronchoscope. Researchers noted no  
24  
25  
26

1 breaches in technique, precleaning or HDL. The researchers noted that even following the  
2 manufacturer's reprocessing procedures there was accumulation of proteinaceous debris and  
3 biofilm allowing subsequent contamination.

4 105. Defendants knew or should have known that at all material times their  
5 communications about the benefits, risks and adverse effects of the Endoscope Devices,  
6 including communications in labels, advertisements and promotional materials, were materially  
7 false and misleading.

8 106. Defendants' nondisclosures, misleading disclosures, and misrepresentations were  
9 material and were substantial factors contributing directly to the serious injuries and damages  
10 Plaintiffs have suffered.

11 107. Decedent would not have agreed to the Endoscope Devices had Defendants  
12 disclosed the true health consequences, risks and adverse effects caused by their Endoscope  
13 Devices.

14 108. Upon information and belief, Defendants failed to conduct adequate pre market  
15 clinical testing and research and failed to conduct adequate post-marketing surveillance to  
16 determine the safety of the Endoscope Devices and the safety and effectiveness of the associated  
17 reprocessing protocol.

18 109. Upon information and belief, Defendants failed to disclose on their warning labels  
19 or elsewhere that adequate pre-market clinical testing and research, and adequate post marketing  
20 surveillance had not been done on the Endoscope Devices, thereby giving the false impression  
21 that the Endoscopic Devices and associated reprocessing protocol had been sufficiently tested.  
22  
23  
24  
25  
26

110. The Endoscope Devices are defective due to Defendants' failure to adequately warn or instruct Decedent and Decedent's medical providers concerning at least the following subjects:

A. The Endoscope Devices' propensities for cracking, degradation, and fragmentation.

B. The risk of harboring microorganisms, including multi-drug-resistant organisms, HIV, and tuberculosis, even after following the protocols outlined in the IFU. resulting from the Devices.

C. The severity of complications that could arise as a result of the use of the Endoscope Devices.

D. Use of the Endoscope Devices is no more effective than with feasible available alternatives, and exposes patients to greater risk than with feasible available alternatives.

E. Use of the Endoscope Devices puts patients at greater risk of developing HIV, tuberculosis, and being infected with multi-drug-resistant organisms requiring extensive hospital stays and IV antibiotics, and resulting in sepsis, organ failure, and other catastrophic injuries, including death than use of feasible available alternatives.

F. Clearing of the infections acquired after the use of the Endoscope Devices may be difficult and, in some cases impossible, resulting in organ failure, septic shock, and death.

G. Due to the inability to clean Defendants' Endoscope Device, medical providers should discard and/or not utilize a reusable Endoscope Device if used in a patient with a communicable disease and/or multi-drug-resistant organisms.

H. The hazards associated with the Endoscope Devices.

I. The Endoscope Devices' defects described in this Complaint.

111. The Endoscope Device used in Decedent was at all times used and reprocessed in a manner foreseeable to Defendants: Defendants generated Product Labeling, Including the Instructions for Use for the Endoscope Device, created procedures for the use, re-use, and reprocessing of the Endoscope Device, and allegedly trained medical providers. But Defendants provided incomplete and insufficient training and information to medical providers regarding the use and reprocessing of the Endoscope Device, as well as instructions and/or warnings about the

1 need to monitor, inspect, and/or visualize the Endoscope Devices to ensure that they are not  
2 damaged, cracked, degraded, and/or contaminated with bacterial microbes or other infectious  
3 organisms prior to using in the next patient, like Decedent.

4 112. The Endoscope Device used in Decedent was in the same or substantially similar  
5 condition as when they left Defendants' possession, and in the condition directed by and  
6 expected by Defendants.

7 113. As a result of having the Endoscope Device used, Decedent experienced  
8 significant physical and mental pain and suffering, sustained permanent injury, underwent  
9 medical treatment, suffered financial or economic loss, including obligations for medical  
10 services and expenses, lost income, and other damages.

11  
12 **V. DISCOVERY RULE; STATUTORY OR EQUITABLE TOLLING; ESTOPPEL**

13 114. Plaintiffs assert all applicable state statutory and common law rights and theories  
14 related to the tolling or extension of any applicable statute of limitations, including statutory and  
15 equitable tolling, delayed discovery, discovery rule, and/or fraudulent concealment.

16 115. The discovery rule applies to toll limitations until Plaintiffs knew, or through the  
17 exercise of reasonable care and diligence should have known, of facts indicating Decedent's  
18 injuries; the cause of the injuries; or the tortious nature of the wrongdoing that caused the  
19 injuries.

20 116. The nature of Decedent's injuries, damages, or their resulting relationship to  
21 Defendants' conduct was not discovered, and through reasonable care and due diligence could  
22 not have been discovered, until a date within the applicable statute of limitations for filing  
23 Plaintiffs' claims.

24 117. Limitations are tolled due to equitable or statutory tolling. Defendants are  
25 therefore estopped from asserting a statute of limitations defense due to their fraudulent  
26

1 concealment, through affirmative misrepresentations and omissions, from Decedent and  
2 Decedent's health care providers of the risks and defects associated with Defendants' Endoscope  
3 Device and associated reprocessing protocol contained in the Product Labeling, including the  
4 severity, duration and frequency of risks and complications. Defendants affirmatively withheld  
5 and/or intentionally misrepresented facts concerning the safety of their Devices, including  
6 adverse data and information from studies and testing conducted with respect to the Endoscope  
7 Devices, showing that the risks and dangers associated with the Endoscope Devices were  
8 unreasonable.  
9

10 118. As a result of Defendants' misrepresentations and concealment, Decedent and  
11 Decedent's health care providers were unaware, and could not have known or have learned  
12 through reasonable diligence, that Decedent had been exposed to the risks alleged in this  
13 Complaint; and that those risks were the direct and proximate result of Defendants' wrongful  
14 acts and/or omissions. Defendants are estopped from asserting any limitations defense based on  
15 their intentional acts of withholding material information about the safety of the Endoscope  
16 Devices from Decedent and Decedent's health care providers.  
17

## 18 COUNT ONE

### 19 STRICT PRODUCT LIABILITY UNDER RCW 7.72.030(1): DEFECTIVE DESIGN

20 119. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

21 120. Defendants' Endoscope Device is defectively designed and unreasonably  
22 dangerous.  
23

24 121. At the time their Endoscope Device was used in Decedent, the Device was  
25 defectively designed. As described in this Complaint, there was an unreasonable risk that a  
26 Device would not perform safely and effectively for the purposes for which it was intended.

1 Defendants failed to design against such dangers and failed to provide adequate warnings and  
2 instructions concerning the risks.

3 122. Defendants' Endoscope Device was defectively designed when supplied, sold,  
4 distributed, and/or otherwise placed into the stream of commerce and when they were used in  
5 Decedent.

6 123. Defendants expected and intended the Endoscope Device to reach users like  
7 Decedent in the condition in which the Devices were sold.

8 124. The usage of Endoscope Device into Decedent was medically reasonable and was  
9 the type of use Defendants intended and foresaw when they designed, manufactured and sold the  
10 Devices.  
11

12 125. The risks of all Endoscope Device' designs significantly outweigh any benefits  
13 allegedly associated with the designs.  
14

15 126. When the Endoscope Device was used in Decedent, there existed safer alternative  
16 designs for such devices, which were economically and technologically feasible at the time the  
17 Devices left Defendants' control. In all reasonable probability, those alternative designs would  
18 have reduced the likelihood, severity, frequency, and duration of the injuries Decedent suffered,  
19 without substantially impairing the utility of the endoscope devices.  
20

21 127. The Endoscope Device used in Decedent failed to reasonably perform as intended  
22 and resulted in complications. In many cases, these complications necessitated further surgery to  
23 repair the injuries caused by the defective Devices, and to repair the very issue the Devices were  
24 intended to repair. Thus, the Devices provided no benefit to Decedent.  
25  
26

1           128. Defendants' Endoscope Device failed consumer safety expectations, as they did  
2 not perform as safely when used in an intended or reasonably foreseeable manner, as an ordinary  
3 consumer would have expected.

4           129. Defendants' Endoscope Device injured Decedent.

5           130. Defendants are strictly liable to Decedent for designing defective products.  
6 Defendants' actions give rise to a claim for damages under the Washington Product Liability Act  
7 ("WPLA"), RCW 7.72 *et seq.*

8           131. Under RCW 7.72.030(1)(a), a manufacturer is subject to liability when the  
9 claimant's harm was proximately caused by the manufacturer's negligence in that the product  
10 was not reasonably safe as designed. A product is not reasonably safe as designed if, at the time  
11 of manufacture, the likelihood that the product would cause the claimant's harm or similar  
12 harms, and the seriousness of those harms, outweighed the burden on the manufacturer to design  
13 a product that would have prevented those harms and the adverse effect that a practical and  
14 feasible alternative design would have had on the product's usefulness. RCW 7.72.030.

15           132. As a direct and proximate result of Defendants' defectively designed Endoscope  
16 Device, Decedent has been injured and undergone medical treatment and died. He also sustained  
17 severe and permanent physical and mental pain, suffering, disability, impairment, loss of  
18 enjoyment of life, loss of care, comfort and consortium, economic loss, and damages, including  
19 medical expenses, lost income, other damages and death.

20           133. Decedent is entitled to recover compensatory, non-compensatory, punitive, and all  
21 other damages available under law for injuries sustained as a result of Defendants' defectively  
22 designed Endoscope Device.

**COUNT TWO**

**STRICT PRODUCT LIABILITY UNDER RCW 7.72.030(1)(b): FAILURE TO WARN**

134. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

135. Defendants were manufacturers, distributors, and/or retailers of the Endoscope Device.

136. Their Devices are inherently dangerous.

137. The use of any of Defendants' Endoscope Device in a reasonably foreseeable manner involves a substantial danger that a user would not readily recognize.

138. Defendants knew or should have known of these dangers, given the generally recognized and prevailing scientific knowledge available at the time of the manufacture and distribution of their Endoscope Device.

139. Defendants failed to provide adequate warning of the dangers created by the reasonably foreseeable use of their Devices.

140. At the time the Devices were used in Decedent, Defendants' warnings and instructions for them were inadequate and defective. As described in this Complaint, there was an unreasonable risk that any Device would not perform safely and effectively for the purposes for which it was intended. Defendants failed to design and/or manufacture against such dangers and failed to provide adequate warnings and instructions concerning these risks.

141. Defendants failed to properly and adequately warn and instruct Decedent and Decedent's health care providers concerning the risks of Endoscope Device, given Decedent's conditions and need for that information.

142. Defendants also failed to properly and adequately warn and instruct Decedent and Decedent's health care providers concerning the inadequate research and testing of Endoscope Device, and the complete lack of a safe, effective procedure for removal of the Devices.

1           143. Defendants expected and intended the Endoscope Device to reach Decedent,  
2 Decedent's health care providers, and other consumers in the condition in which their products  
3 were sold.

4           144. Decedent and Decedent's health care providers were unaware of the defects and  
5 dangers of Endoscope Device; and were further unaware of the frequency, severity, and duration  
6 of the defects and risks associated with the Devices.

7           145. Defendants' Instructions for Use for the Devices expressly understated, misstated,  
8 or concealed the risks Defendants knew or should have known were associated specifically with  
9 them, as described in this Complaint.

10           146. Defendants' Instructions for Use for the Endoscope Device failed to adequately  
11 warn Decedent or Decedent's health care providers of numerous risks Defendants knew or  
12 should have known were associated with the Devices.

13           147. Defendants failed to adequately train or warn Decedent or Decedent's health care  
14 providers about the necessity for surgical intervention in the event of complications, or how to  
15 properly treat such complications associated with the Endoscope Device when they occurred.

16           148. With respect to Defendants' warnings about complications associated with the  
17 Devices, they provided inadequate or no information regarding the complications, frequency,  
18 severity, and duration, even though the complications were more frequent and more severe and  
19 lasted longer than those associated with safer feasible alternative treatments.

20           149. If Decedent or Decedent's health care providers had been properly warned of the  
21 defects and dangers of Endoscope Device, and of the frequency, severity and duration of the  
22 risks associated with the Devices, Decedent would not have consented to allow the Devices to be  
23 used, nor would Decedent's health care providers have used them.

1           150. Defendants are strictly liable in tort to Decedent for their wrongful conduct,  
2 including their failure to warn or provide adequate instructions regarding Endoscope Device.

3           151. Defendants' actions give rise to a claim for damages under the WPLA. Under  
4 RCW 7.72.030(1)(b), a product is not reasonably safe because adequate warnings or instructions  
5 were not provided with the product if, at the time of manufacture, the likelihood that the product  
6 would cause the claimant's harm or similar harms, and the seriousness of those harms, rendered  
7 the manufacturer's warnings or instructions inadequate, and the manufacturer could have  
8 provided adequate warnings.  
9

10           152. Washington courts apply strict liability to failure to warn claims under RCW  
11 7.72.030(1)(b) for dangers known at the time of manufacture.

12           153. As a direct and proximate result of Defendants' inadequate and defective  
13 warnings and instructions, Decedent has been injured and undergone medical treatment and died.  
14 Decedent has also sustained severe and permanent physical and mental pain, suffering, disability,  
15 impairment, loss of enjoyment of life, loss of care, comfort and consortium, economic loss, and  
16 damages, including medical expenses, lost income, and other damages and death.  
17

18           154. Plaintiff's injuries were a reasonably foreseeable result of Defendants' failure to  
19 provide adequate warnings and instructions.  
20

21           155. Decedent is entitled to recover compensatory, non-compensatory, punitive, and all  
22 other damages available under law for injuries sustained as a result of Defendants' failure to  
23 provide adequate warnings and instructions on the risks and dangers associated with their  
24 Endoscope Device.

25           156. As a result of Defendants' failure to warn or to provide adequate warnings,  
26 Decedent or Decedent's health care providers were unaware, and could not have known or

1 learned through reasonable diligence, that Decedent had been exposed to the risks alleged in this  
2 Complaint; and that those risks were the direct and proximate result of Defendants' wrongful  
3 acts and/or omissions.

4  
5 **COUNT THREE**

6 **STRICT PRODUCT LIABILITY UNDER RCW 7.72.030(2): MANUFACTURING DEFECT**

7 157. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

8 158. Defendants' Endoscope Device was not reasonably safe for their intended use and  
9 were defective with respect to their manufacture, in that they deviated materially from  
10 Defendants' manufacturing and/or design specifications and thus posed unreasonable risks of  
11 serious bodily harm to Decedent.

12 159. Defendants' Endoscope Device was unreasonably dangerous as a result of a  
13 malfunction, failure to properly manufacture to specifications as intended, improper assembly, or  
14 improperly broken or damaged packaging.

15 160. At the time the Endoscope Device was used, the Devices were defective with  
16 respect to their manufacture, in that Defendants deviated materially from their manufacturing  
17 and/or design specifications and thus posed an unreasonable risk of harm to Decedent in whom  
18 the Endoscope Device was used.

19 161. The manufacturing defects associated with the Endoscope Device were not  
20 known, knowable or readily visible to Decedent's health care providers or to Decedent, nor were  
21 they discoverable upon reasonable examination. The Endoscope Device was used and used in the  
22 very manner in which they were intended to be used and used, in accordance with Defendants'  
23 Instructions for Use and marketing materials.  
24  
25  
26

1           162. The Endoscope Device used in Decedent were different from their intended  
2 design and failed to perform as safely as Devices manufactured in accordance with the intended  
3 design would have performed.

4           163. As a direct and proximate result of the aforementioned defects, Decedent has been  
5 injured and undergone medical treatment and death. Decedent has also sustained severe and  
6 permanent physical and mental pain, suffering, disability, impairment, loss of enjoyment of life,  
7 loss of care, comfort and consortium, economic loss, and damages, including medical expenses,  
8 lost income, other damages and death.

9           164. Defendants' defective manufacture of Endoscope Device was a proximate cause  
10 of the damages and injuries Decedent suffered.

11           165. Defendants are strictly liable to Decedent for designing, manufacturing,  
12 marketing, labeling, packaging and selling defective Endoscope Device.

13           166. Defendants' actions give rise to a claim for damages under the WPLA. Under  
14 RCW 7.72.030(2)(a), a manufacturer is subject to strict liability when the claimant's harm was  
15 proximately caused by the fact that the product was not reasonably safe in construction. A  
16 product is not reasonably safe in construction if, when the product left the control of the  
17 manufacturer, it deviated in some material way from otherwise identical units of the same  
18 product line or was and is improperly manufactured.

19           167. The WPLA does not shield medical device manufacturers from strict liability for  
20 manufacturing defects, and strict liability therefore remains fully available for manufacturing  
21 defect claims against medical device manufacturers.

168. Decedent is entitled to recover compensatory, non-compensatory, punitive, and all other damages available under law for injuries sustained as a result of Defendants' defectively manufactured Endoscope Device.

**COUNT FOUR**

**NEGLIGENCE**

169. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

170. Defendants owed a duty to Decedent to exercise reasonable care when designing, manufacturing, producing, marketing, labeling, packaging and selling Defendants' Endoscope Device, and when creating instructions and warnings for them.

171. Defendants did not exercise reasonable care when designing, manufacturing, producing, labeling, packaging, marketing, selling, creating, and explaining the instructions or warnings for the Devices.

172. In addition to the acts and omissions described in this Complaint, Defendants, by and through their authorized divisions, subsidiaries, agents, servants and/or employees, acted with carelessness, recklessness, negligence, gross negligence and/or willful, wanton, outrageous and reckless disregard for human life and safety in manufacturing, designing, labeling, creating instructions and warnings, marketing, distributing, supplying, selling and/or placing into the stream of commerce their Endoscope Device, including but not limited to the following:

A. failing to use due care in design and/or manufacture of the Endoscope Devices so as to avoid the aforementioned risks to Decedent and others;

B. failing to conduct adequate testing, including pre-clinical and clinical testing and post-marketing surveillance to determine the safety of their Endoscope Devices;

C. failing to recognize the significance of their own and other testing, and information regarding their Endoscope Devices, which testing and information evidenced such products are dangerous and potentially harmful when used in humans;

1 D. failing to respond promptly and appropriately to their own and other  
2 testing, and information regarding the Endoscope Devices; and failing to promptly and  
adequately warn of the injuries as described in this Complaint;

3 E. failing to promptly, adequately and appropriately recommend monitoring  
4 of patients used with the Endoscope Devices, in light of the Devices' dangers and  
potential harm to humans;

5 F. failing to properly, appropriately and adequately monitor the post-market  
6 performance of their Endoscope Devices;

7 G. aggressively promoting, marketing, advertising and/or selling their  
8 Endoscope Devices despite their knowledge and experience of the Devices' dangers and  
risks;

9 H. failing to use reasonable and prudent care in their statements of the  
10 efficacy, safety and risks of using the Endoscope Devices, which were knowingly false  
and misleading, in order to influence patients' health care providers to use the Devices;

11 I. failing to accompany their Endoscope Devices with proper and adequate  
12 warnings regarding all possible adverse effects and risks associated with the usage of the  
13 Devices;

14 J. failing to disclose to Decedent or Decedent's health care providers their  
15 full knowledge and experience regarding the potential risks and harm associated with the  
usage of the Endoscope Devices;

16 K. failing to disclose to Decedent or Decedent's health care providers in an  
17 appropriate and timely manner, facts relative to the potential risks and harm associated  
with the usage of the Endoscope Devices;

18 L. failing to warn Decedent or Decedent's health care providers of the  
19 severity and duration of such adverse effects;

20 M. failing to warn Decedent or Decedent's health care providers directly or  
21 indirectly, whether orally or in writing, before actively encouraging the sale of their  
Endoscope Devices, about the increased risk associated with the Devices;

22 N. placing and/or permitting the placement of the Endoscope Devices into the  
23 stream of commerce without adequate warnings that their usage is harmful to humans  
and/or without proper warnings of the Devices' risks;

24 O. failing to respond or react promptly and appropriately to reports that the  
25 Endoscope Devices caused harm to patients;

26 P. disregarding government and/or industry studies, information,  
documentation and recommendations, consumer complaints and reports or other

1 information regarding the hazards of usage of the Endoscope Devices and their potential  
2 harm to humans;

3 Q. under-reporting, underestimating or downplaying the serious dangers and  
4 risks of their Endoscope Devices;

5 R. failing to exercise reasonable care in informing health care providers using  
6 the Endoscope Devices about Defendants' own knowledge regarding the potential risks  
7 and harm associated with the usage of the Devices;

8 S. failing to adequately warn Decedent or Decedent's health care providers  
9 of the known or reasonably foreseeable danger that Decedent would suffer serious  
10 injuries or death after being used with their Endoscope Devices;

11 T. promoting the Endoscope Devices in advertisements, websites and other  
12 modes of communication aimed at creating or increasing the rate and frequency of usage  
13 of the Devices, without regard to the dangers and risks associated with their usage;

14 U. failing to conduct or respond to post-marketing surveillance of  
15 complications and injuries associated with the use of the Endoscope Devices;

16 V. failing to use due care under the circumstances; and

17 W. other acts or omissions constituting negligence and carelessness, as may  
18 appear during the course of discovery or at the trial of this matter.

19 173. Defendants knew or should have known that their failure to exercise ordinary care  
20 in the manufacture, design, packaging, labeling, the creation of warnings and instructions, sale,  
21 marketing and distribution of the Devices, and their training of health care providers to use the  
22 Devices or to treat Device complications, would cause foreseeable harm, injuries, and damages  
23 to individuals used with Endoscope Devices, including Decedent.

24 174. Defendants knew, or in the exercise of reasonable care should have known, that  
25 the Endoscope Device was defectively and unreasonably manufactured and/or designed, and  
26 were unreasonably dangerous and likely to injure patients in whom Endoscope Device was used.  
Defendants knew or should have known that Decedent or Decedent's health care providers were  
unaware of the dangers and defects inherent in the Devices.

175. Defendants' Endoscope Device caused Decedent to suffer injuries.



1 allow—and for which Decedent will seek at the appropriate time under governing law—the  
2 imposition of exemplary damages. Defendants’ conduct was specifically intended to cause  
3 substantial injury to Decedent, or when viewed objectively from Defendants’ standpoint at the  
4 time of the conduct, involved an extreme degree of risk, considering the probability and  
5 magnitude of the potential harm to others. Further, Defendants were actually subjectively aware  
6 of the risk involved, but nevertheless proceeded with conscious indifference to the rights, safety,  
7 or welfare of others, including Decedent. Defendants’ outrageous conduct warrants an award of  
8 punitive damages.  
9

10 183. As a direct and proximate result of Defendants’ gross negligence, Decedent has  
11 been injured and undergone medical treatment and died. Decedent has also sustained severe and  
12 permanent physical and mental pain, suffering, disability, impairment, loss of enjoyment of life,  
13 loss of care, comfort and consortium, economic loss, and damages, including medical expenses,  
14 lost income, other damages and death.  
15

16 184. Plaintiffs allege that the acts and omissions of Defendants, whether taken alone or  
17 in combination with others, constitute gross negligence that proximately caused the injuries to  
18 Decedent. In that regard, Plaintiffs will seek exemplary damages in an amount to punish  
19 Defendants for their conduct, and to deter other manufacturers from engaging in such  
20 misconduct in the future.  
21

## 22 COUNT SIX

### 23 BREACH OF IMPLIED WARRANTY UNDER THE WPLA

24 185. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

25 186. Defendants sold the Endoscope Device used in Decedent.  
26

1           187. Defendants knew or reasonably should have known at the time of sale, that each  
2 Endoscope Device was intended to be used for the purpose of introduction into the human body  
3 and reprocessing before additional usage on another patient.

4           188. Defendants warranted to Decedent, Decedent's health care providers, and other  
5 consumers, that the Devices were of merchantable quality, and safe for the use for which they  
6 were intended.

7           189. Decedent or Decedent's health care providers reasonably relied on Defendants'  
8 judgment, indications, and statements that Endoscope Device was fit for such use. Because of  
9 that reliance, Defendants' Endoscope Device was used in Decedent.

10           190. Defendants distributed into the stream of commerce and sold Endoscope Device  
11 that were unsafe for their intended use, and not of merchantable quality as warranted by  
12 Defendants, in that the Devices had dangerous propensities when used as intended and used.

13           191. Under RCW 7.72.030(2)(c), a manufacturer is subject to strict liability when the  
14 product did not conform to the implied warranties under Title 62A RCW (Washington's Uniform  
15 Commercial Code). Defendants' Endoscope Device does not conform to Title 62A for the  
16 reasons set forth herein.

17           192. As a result of Defendants' conduct, Decedent suffered injuries and damages,  
18 making Defendants liable for breaching their implied warranties.

19           193. As a direct and proximate result of Defendants' breach of the implied warranties  
20 associated with their Endoscope Device, Decedent has been injured and undergone medical  
21 treatment and died. Decedent has also sustained severe and permanent physical and mental pain  
22 and suffering, disability, impairment, loss of enjoyment of life, loss of care, comfort and  
23  
24  
25  
26

1 consortium, economic loss, and damages, including medical expenses, lost income, other  
2 damages and death.

3 **COUNT SEVEN**

4 **BREACH OF EXPRESS WARRANTY UNDER THE WPLA**

5 194. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

6 195. Defendants warranted and represented to Decedent, Decedent's health care  
7 providers, and other consumers, that their Endoscope Device was safe and reasonably fit for their  
8 intended purposes.

9 196. Decedent or Decedent's health care providers chose Endoscope Device based  
10 upon Defendants' warranties and representations regarding the safety and fitness of their  
11 Endoscope Device, as described in this Complaint.

12 197. Decedent or Decedent's health care providers reasonably relied upon Defendants'  
13 express warranties and guarantees that the Devices were safe, merchantable, and reasonably fit  
14 for their intended purposes.

15 198. Defendants breached these express warranties because their Endoscope Device  
16 was unreasonably dangerous and defective, and not as Defendants had represented them to be.  
17 Defendants' breach of their express warranties resulted in the usage of unreasonably dangerous  
18 and defective Endoscope Device in Decedent, placing Decedent's health and safety in jeopardy.

19 199. Under RCW 7.72.030(2)(b), a manufacturer is subject to strict liability when the  
20 product does not conform to the manufacturer's express warranty. A product does not conform to  
21 an express warranty if the warranty was made part of the basis of the bargain, relates to a  
22 material fact or facts concerning the product, and the express warranty proved to be untrue. An  
23 express warranty under the WPLA is generally an affirmation of fact that may tend to induce use  
24 of the product.  
25  
26

## NEGLIGENT INFLICTION OF EMOTIONAL DISTRESS

202. As described in this Complaint, Defendants engaged in negligent conduct by failing to use due care in adequately designing and constructing effective and safe Endoscope Device, by failing to warn of their dangerous propensities, and by negligently studying, designing, developing, testing, inspecting, manufacturing, advertising, marketing, promoting, labeling, distributing, and/or selling the Endoscope Device.

204. The emotional distress damages Decedent incurred were a reasonably foreseeable result of Defendants' actions.

## INTENTIONAL INFLICTION OF EMOTIONAL DISTRESS

206. As described in this Complaint, Defendants engaged in intentional, willful, reckless, extreme, and outrageous conduct by failing to adequately design and construct effective and safe Endoscope Device, by failing to warn of their dangerous propensities, and by

1 improperly studying, designing, developing, testing, inspecting, manufacturing, advertising,  
2 marketing, promoting, labeling, distributing, and/or selling the Devices.

3 207. The emotional distress damages Plaintiffs incurred were a reasonably foreseeable  
4 result of Defendants' actions.

5  
6 **COUNT TEN**

7 **NEGLIGENT MISREPRESENTATION**

8 208. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

9 209. From the time Defendants' Endoscope Device was first tested, studied,  
10 researched, evaluated, endorsed, manufactured, marketed and distributed, through the present,  
11 Defendants made misrepresentations to Decedent, Decedent's health care providers, and the  
12 general public. Defendants' misrepresentations included but were not limited to representing that  
13 reprocessed Endoscope Device was safe and effective for the introduction to the human body. At  
14 all relevant times, Defendants conducted sales and marketing campaigns to promote the sale and  
15 usage of the Endoscope Device and willfully deceived Decedent, Decedent's health care  
16 providers, and the general public as to the health risks and consequences of the usage of the  
17 Endoscope Device.

18  
19 210. Defendants had a duty to ensure that the representations they made about their  
20 Endoscope Device were true and complete when made. Defendants made the foregoing  
21 representations without any reasonable ground for believing them to be true and complete.

22  
23 211. At all relevant times, Defendants conducted sales and marketing campaigns to  
24 promote the sale and usage of their Endoscope Device and deceived Decedent or Decedent's  
25 health care providers, as well as other consumers, as to the health risks and consequences of the  
26 use of their Endoscope Device.

1           212. Defendants made these false and misleading representations concerning the safety  
2 and efficacy of Endoscope Device for the reprocessed usage in the human body without any  
3 reasonable ground for believing them to be true.

4           213. These false and misleading representations were made directly by Defendants,  
5 their sales representatives and other authorized agents, to Decedent, Decedent's health care  
6 providers and the general public, in publications, the popular press, and other written materials  
7 directed to them; and on Internet websites and applications also directed to them, with the  
8 intention of inducing and influencing the demand for, and the ultimate usage of, their Endoscope  
9 Device in Decedent and other patients.  
10

11           214. The above representations were in fact false, in that Defendants' Endoscope  
12 Device was not safe, fit or effective for usage as labeled; using the reprocessed Endoscope  
13 Device was hazardous to consumers' health; and the Endoscope Device had a propensity to  
14 cause serious injuries to patients, as described in this Complaint.  
15

16           215. Defendants' representations were made with the intention of inducing reliance  
17 and the ultimate usage of the Endoscope Device on Decedent and other patients.

18           216. In reliance on Defendants' false and misleading representations, Decedent's  
19 health care providers were induced to purchase and recommend usage of the Devices on  
20 Decedent; and Decedent were induced to consent to such usage. If Decedent or Decedent's  
21 health care providers had known the truth and the facts Defendants concealed, the health care  
22 providers would not have recommended, and Decedent would not have consented to, the usage  
23 of Defendants' Endoscope Device. The reliance of Decedent and/or Decedent's health care  
24 providers on Defendants' misrepresentations was justified because such misrepresentations were  
25 made and conducted by individuals and entities in a position to know all facts.  
26

1           217. Defendants' acts and omissions caused Decedent to suffer serious injuries that are  
2 permanent and lasting in nature: death; physical pain and mental anguish; diminished enjoyment  
3 of life; and financial expenses for hospitalization and medical care.

4           218. Defendants' conduct, as described in this Complaint, was extreme and  
5 outrageous. Defendants risked the lives of the recipients of these Devices, including Decedent,  
6 with knowledge of the safety and efficacy problems with their Endoscope Device and suppressed  
7 this knowledge from the general public, Decedent, and/or Decedent's health care providers.  
8 Defendants made conscious decisions not to redesign, re-label, warn or inform the unsuspecting  
9 consuming public. Defendants' outrageous conduct warrants an award of punitive damages.

## 11                                   COUNT ELEVEN

### 12                           FRAUD AND FRAUDULENT MISREPRESENTATION

13           219. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

14           220. Defendants designed, manufactured, marketed, and sold their Endoscope Device,  
15 and provided inadequate warnings and information about the Endoscope Device.

16           221. When Decedent or Decedent's healthcare providers received inadequate  
17 information and warnings, the Devices were defective and unreasonably dangerous for their  
18 intended and reasonably foreseeable use.

19           222. Further, Defendants fraudulently represented to Decedent, Decedent's health care  
20 providers, and the general public that their Endoscope Device was safe and effective.  
21 Additionally, even though Defendants were fully aware of the dangerous and defective nature of  
22 the Endoscope Device, which could and did cause injuries such as those Decedent suffered,  
23 Defendants intentionally concealed the defects in the Endoscope Device from Decedent.  
24  
25  
26

1           223. Defendants fraudulently represented to Decedent, Decedent's health care  
2 providers, and the general public, that their Endoscope Device had been adequately tested, were  
3 safe for introduction into the human body, and were accompanied by adequate warnings.

4           224. Defendants widely advertised, marketed and promoted their Endoscope Device as  
5 safe and effective for usage in the human body after repeated use and disinfection in accordance  
6 with the IFU and/or Product Labeling.

7           225. Defendants made these representations with the intent of deceiving Decedent,  
8 Decedent's health care providers, and other potential consumers; and with the intent of inducing  
9 the usage of their Endoscope Device, under circumstances that Defendants knew were dangerous  
10 and unsafe, and created a high risk of harm.

11           226. Defendants also made material representations that were false. Further,  
12 Defendants knew they were false when made, or willfully, wantonly, and recklessly disregarded  
13 whether the representations were true or false. Defendants intended that Decedent, Decedent's  
14 health care providers, and other potential consumers would rely and act upon the false  
15 representations.

16           227. Decedent and/or Decedent's health care providers relied upon Defendants'  
17 fraudulent misrepresentations in allowing the defective Endoscope Device to be used. Decedent  
18 thus sustained severe and permanent personal injuries, and/or were at an increased risk of  
19 sustaining severe and permanent personal injuries in the future.

20           228. Defendants knew or should have known that their Endoscope Device had not been  
21 sufficiently tested, were defective in nature and/or lacked adequate warnings and information.

22           229. As a direct and proximate result of Defendants' fraud or fraudulent  
23 misrepresentation, Decedent has been injured and undergone medical treatment and died.

Decedent has also sustained severe and permanent physical and mental pain, suffering, disability, impairment, loss of enjoyment of life, loss of care, comfort and consortium, economic loss, and damages, including medical expenses, lost income, other damages and death.

## COUNT TWELVE

### FRAUDULENT CONCEALMENT

230. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

231. Before Defendants' Endoscope Device was used on Decedent, Defendants fraudulently concealed material information regarding the safety and efficacy of their Endoscope Device, including information regarding adverse events, pre-marketing and post-marketing injuries, and literature indicating unreasonable risks associated with the usage of the Endoscope Device.

232. Although Defendants were aware of the dangerous and defective condition of the Endoscope Device, they intentionally concealed such information from Decedent, Decedent's health care providers, and the general public. The significant dangers Defendants concealed included sufficient warnings about the degradation and damage to the Endoscope Device, the difficulty of reprocessing, the usage of validating tests like dryness indicators and microbiology testing, and sterilization instead of HLD. Further, the dangers were not readily obvious to the ordinary user of the Devices, even after post-usage complications had arisen.

233. Defendants made these omissions with the intent of defrauding and deceiving Decedent or Decedent's health care providers specifically, and other consumers generally; and with the further intent of specifically inducing health care providers to recommend usage of the Endoscope Device. All such acts and omissions evinced Defendants' callous, reckless, willful, depraved indifference to the health, safety and welfare of Decedent.

1           234. When Defendants made the foregoing partial disclosures and fraudulent  
2 omissions, and at the time Decedent were exposed to the Endoscope Device, Decedent and/or  
3 Decedent's health care providers were unaware of their falsity and reasonably believed the  
4 misrepresentations and omissions to be true.

5           235. Defendants fraudulently concealed the safety issues associated with the usage of  
6 their Endoscope Device, to induce health care providers to recommend usage of the Endoscope  
7 Device in patients like Decedent, and to induce Decedent to consent to the usage of the  
8 Endoscope Device.

9           236. Decedent's health care providers reasonably relied on Defendants' omissions  
10 when they recommended usage of the Endoscope Device used on Decedent, thereby causing  
11 Decedent to sustain severe and permanent personal injuries. Defendants knew, or should have  
12 known, that their Endoscope Device had not been sufficiently tested and were defective in  
13 nature, and/or that their Endoscope Device lacked adequate warnings.

14           237. Defendants also knew or should have known that their Endoscope Device has  
15 potential to, and would, cause severe injury to those exposed to their Devices, and that the  
16 Endoscope Device was inherently dangerous in a manner exceeding any purported warnings.

17           238. Defendants had a duty to provide Decedent, Decedent's health care providers, and  
18 the general public, with full, complete, accurate and truthful information concerning their  
19 Endoscope Device.

20           239. By virtue of Defendants' omissions and partial disclosures about the Endoscope  
21 Device, in which Defendants touted their Devices as safe and effective for usage in patients,  
22 Defendants had a duty to disclose all facts about the risks associated with the Devices, including  
23 the risks described in this Complaint.  
24  
25  
26

1           240. Decedent's health care providers reasonably relied on these material and  
2 fraudulent omissions when recommending usage of the Endoscope Device in Decedent, and  
3 Decedent reasonably relied on the material and fraudulent omissions when consenting to have  
4 the Devices used.

5           241. Defendants did not provide Decedent's health care providers with the information  
6 necessary to adequately warn Decedent.

7           242. The Endoscope Device was improperly marketed to Decedent and Decedent's  
8 health care providers because Defendants did not provide proper instructions on how to use the  
9 Devices and did not adequately warn about the risks associated with usage.

10           243. Decedent could not know in the exercise of reasonable diligence that Defendants'  
11 statements concerning their Endoscope Device was knowingly and intentionally false and  
12 misleading, or that Defendants had not disclosed material facts and information to Decedent or  
13 Decedent's health care providers that would have been material to the choice of treatment.

14           244. As a direct and proximate result of Defendants' malicious and intentional  
15 concealment of material information from Decedent and/or Decedent's health care providers,  
16 Defendants caused or contributed to Decedent's injuries and death.

17           245. Had Decedent's health care providers been aware of the hazards associated with  
18 the usage of Defendants' Endoscope Device, they would have used safer alternative devices for  
19 the Decedent's endoscopic procedure.

20           246. Defendants' conduct was reckless, willful, wanton, and outrageous, and  
21 manifested a reckless indifference for the safety and well-being of Decedent and other  
22 consumers.

1           247. As a direct and proximate result of Defendants' intentional and willful fraudulent  
2 concealment of material facts and information from Decedent and/or Decedent's health care  
3 providers, Defendants caused and increased the risk of harm of the injuries and damages  
4 Decedent suffered after having been used with Defendants' Endoscope Device.

5           248. Had Decedent been aware of the hazards associated with the usage of the  
6 Endoscope Device, they would not have consented to its use.

7           249. Defendants actively and fraudulently concealed information in their exclusive  
8 possession regarding the hazards associated with the usage of their Endoscope Device, for the  
9 purpose of preventing Decedent or Decedent's health care providers from discovering these  
10 hazards.  
11

12           250. Defendants' conduct was outrageous and shocked the conscience, and knowingly  
13 and intentionally placed considerations of financial gain, revenues and profits, market share and  
14 marketing advantage over patient safety and well-being.  
15

16           251. As a result of the foregoing material and fraudulent omissions, Decedent were  
17 caused to suffer serious injuries as described in this Complaint, which are permanent and lasting  
18 in nature, physical pain and mental anguish, diminished enjoyment of life and financial expenses  
19 for hospitalization and medical care.  
20

21           252. Defendants' conduct risked the lives of Decedent and other consumers and users  
22 of their products. Although Defendants had knowledge of the safety and efficacy problems with  
23 their Devices, they concealed this knowledge from Decedent, Decedent's health care providers,  
24 and the general public. Further, Defendants made conscious decisions not to redesign, re-label,  
25 or warn unsuspecting consumers. Defendants' outrageous conduct warrants an award of punitive  
26 damages.

**COUNT THIRTEEN**

**OUTRAGE**

253. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

254. Defendants' conduct, as described in this Complaint, went beyond all possible bounds of decency and can only be regarded as atrocious and intolerable.

255. Defendants' conduct was extreme and outrageous.

256. Defendants, by their outrageous conduct, intentionally and/or recklessly caused Plaintiffs severe emotional distress, physical pain, and death.

**COUNT FOURTEEN**

**WRONGFUL DEATH**

257. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

258. This wrongful death claim is brought on behalf of the estate and for the benefit of the lawful beneficiaries of Decedent.

259. As a proximate result of Defendants' conduct and the defective nature of their Endoscope Device as described in this Complaint, Decedent suffered bodily injury resulting in pain and suffering, disability, disfigurement, mental anguish, loss of capacity of the enjoyment of life, shortened life expectancy, expenses for hospitalization, medical and nursing treatment, loss of earnings, loss of ability to earn, funeral expenses and death.

260. By reason of the death of Decedent, Decedent's heirs, next-of-kin and/or survivors (collectively beneficiaries) have suffered a pecuniary or non-pecuniary loss, including but not limited to support, income, services and guidance of Decedents. All were permanently damaged as a result.

261. The beneficiaries have incurred hospital, nursing and medical expenses, and estate administration expenses as a result of the Decedent's death caused by Defendants' wrongful

1 conduct. The beneficiaries bring these claims for damages and for all pecuniary losses they  
2 sustained, pursuant to applicable state law.

3 **COUNT FIFTEEN**

4 **LOSS OF CONSORTIUM**

5 262. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

6 263. At all material times, Decedent had a spouse who also suffered injuries and losses  
7 as a result of Defendants' Endoscope Device. As a direct and proximate result of Defendants'  
8 conduct, Plaintiff Michelle Bruto Da Costa has suffered and will continue to suffer the loss of  
9 Decedent's support, companionship, services, society, love, and affection.

10 264. Plaintiff has suffered emotional pain and mental anguish.

11 265. Plaintiff has sustained and will continue to sustain physical injuries, severe  
12 emotional distress, economic losses, and other harm for which they are entitled to damages.  
13

14 **COUNT SIXTEEN**

15 **PUNITIVE DAMAGES**

16 266. Plaintiffs reallege and incorporate by reference all paragraphs in this Complaint.

17 267. Defendants sold Endoscope Device to health care providers throughout the United  
18 States, without conducting adequate testing to ensure that the Devices were reasonably safe for  
19 usage.  
20

21 268. Defendants knew their Devices posed unreasonable risks, including developing  
22 tuberculosis, HIV, and being infected with multi-drug-resistant organisms or other infections  
23 requiring extensive hospital stays and IV antibiotics and resulting in sepsis and sequalae of  
24 sepsis, organ failure and/or other catastrophic injuries.

25 269. Defendants sold their Endoscope Device to health care providers throughout the  
26 United States, despite knowing of these unreasonable risks.

1           270. At all material times, Defendants attempted to misrepresent and did misrepresent  
2 facts concerning the safety of their Endoscope Device, including adverse data and information  
3 from studies and testing conducted with respect to the Devices, which showed that the risks and  
4 dangers associated with the Devices were unreasonable.

5           271. Defendants' misrepresentations, omissions, and partial disclosures, included  
6 knowingly withholding material information from the medical community and the public,  
7 including Decedent, concerning the safety and efficacy of Defendants' Endoscope Device.

8           272. At all material times, Defendants knew and intentionally and/or recklessly  
9 disregarded the fact that their Endoscope Device caused severe and potentially permanent  
10 complications with greater frequency than safer and feasible alternative devices or treatments.

11           273. Notwithstanding that knowledge, Defendants continued to market their  
12 Endoscope Device to consumers without disclosing the true risk of side effects and  
13 complications, or the frequency, severity and duration of those risks.

14           274. Defendants knew of their Devices' defective and unreasonably dangerous nature.  
15 But they continued to manufacture, produce, assemble, market, distribute, and sell the Devices,  
16 and failed to include adequate warnings about them. Defendants' acts and omissions were taken  
17 with reckless disregard of the foreseeable harm caused by the Endoscope Device, so as to  
18 maximize sales and profits at the expense of the health and safety of the public, including  
19 Decedent.

20           275. Defendants' conduct described in this Complaint shows willful misconduct,  
21 malice, fraud, wantonness, oppression, or that entire want of care raising the presumption of  
22 conscious indifference to consequences. Therefore, an award of punitive damages is justified.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs demand judgment against Defendants, jointly and severally, on each of the above claims or causes of action, as follows:

A. Compensatory damages in excess of \$75,000, including, but not limited to damages for pain, suffering, discomfort, physical impairment, emotional distress, loss of enjoyment of life, loss of consortium, wrongful death, and other noneconomic damages in an amount to be determined at trial;

B. economic damages in the form of medical expenses, out-of-pocket expenses, lost earnings and other economic damages, in an amount to be determined at trial;

C. punitive or exemplary damages for Defendants' wanton, willful, fraudulent, and reckless acts, established by their demonstration of complete disregard and reckless indifference for the safety and welfare of Decedent and the general public, in an amount sufficient to punish Defendants and deter future similar conduct;

D. prejudgment interest;

E. post-judgment interest;

F. an award of reasonable attorneys' fees;

G. costs of these proceedings; and

H. any further relief this Court deems just and proper.

**JURY DEMAND**

Plaintiffs demand a trial by jury as to all issues triable by jury.

DATED this 5th day of June, 2026.

KELLER ROHRBACK L.L.P.

By: /s David J. Ko

David J. Ko, WSBA #38299

1201 Third Avenue, Suite 3400

Seattle, WA 98101-3268

Telephone: (206) 623-1900

Facsimile: (206) 623-3384

Email: dko@kellerrohrback.com

James Caleb Cunningham, *Pro hac vice*  
*forthcoming*  
Florida Bar No. 0120236  
Alabama Bar No. 6629C83U  
Missouri Bar No. 70471  
LEVIN, PAPANTONIO, PROCTOR,  
BUCHANAN, O'BRIEN, BARR & MOUGEY,  
P.A.  
316 S. Baylen Street, Suite 600  
Pensacola, FL 32502-5996  
850.435.7018 (office)  
850.436.6018 (fax)  
ccunningham@levinlaw.com

***Attorneys for Plaintiffs***

## CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

**I. (a) PLAINTIFFS**

Michelle Bruto Da Costa, Individually and as personal representative of the Estate of Mark Bruto Da Costa,

(b) County of Residence of First Listed Plaintiff Snohomish  
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number)

Keller Rohrback L.L.P., 1201 Third Ave., Ste 3400,  
Seattle, WA 98101, 206-623-1900

**DEFENDANTS**

Olympus America Inc., Olympus Corporation, Olympus Medical Systems Corp., Olympus Corporation of the

County of Residence of First Listed Defendant \_\_\_\_\_  
(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

**II. BASIS OF JURISDICTION** (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff ☐ 3 Federal Question (U.S. Government Not a Party)
- ☐ 2 U.S. Government Defendant ☒ 4 Diversity (Indicate Citizenship of Parties in Item III)

**III. CITIZENSHIP OF PRINCIPAL PARTIES** (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- |                                         | PTF                                   | DEF                        |                                                               | PTF                        | DEF                                   |
|-----------------------------------------|---------------------------------------|----------------------------|---------------------------------------------------------------|----------------------------|---------------------------------------|
| Citizen of This State                   | <input checked="" type="checkbox"/> 1 | <input type="checkbox"/> 1 | Incorporated or Principal Place of Business In This State     | <input type="checkbox"/> 4 | <input type="checkbox"/> 4            |
| Citizen of Another State                | <input type="checkbox"/> 2            | <input type="checkbox"/> 2 | Incorporated and Principal Place of Business In Another State | <input type="checkbox"/> 5 | <input checked="" type="checkbox"/> 5 |
| Citizen or Subject of a Foreign Country | <input type="checkbox"/> 3            | <input type="checkbox"/> 3 | Foreign Nation                                                | <input type="checkbox"/> 6 | <input type="checkbox"/> 6            |

**IV. NATURE OF SUIT** (Place an "X" in One Box Only)

Click here for: [Nature of Suit Code Descriptions.](#)

| CONTRACT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | TORTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | FORFEITURE/PENALTY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | BANKRUPTCY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | OTHER STATUTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> 110 Insurance<br><input type="checkbox"/> 120 Marine<br><input type="checkbox"/> 130 Miller Act<br><input type="checkbox"/> 140 Negotiable Instrument<br><input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment<br><input type="checkbox"/> 151 Medicare Act<br><input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excludes Veterans)<br><input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits<br><input type="checkbox"/> 160 Stockholders' Suits<br><input type="checkbox"/> 190 Other Contract<br><input type="checkbox"/> 195 Contract Product Liability<br><input type="checkbox"/> 196 Franchise | <b>PERSONAL INJURY</b><br><input type="checkbox"/> 310 Airplane<br><input type="checkbox"/> 315 Airplane Product Liability<br><input type="checkbox"/> 320 Assault, Libel & Slander<br><input type="checkbox"/> 330 Federal Employers' Liability<br><input type="checkbox"/> 340 Marine<br><input type="checkbox"/> 345 Marine Product Liability<br><input type="checkbox"/> 350 Motor Vehicle<br><input type="checkbox"/> 355 Motor Vehicle Product Liability<br><input type="checkbox"/> 360 Other Personal Injury<br><input type="checkbox"/> 362 Personal Injury - Medical Malpractice<br><b>PERSONAL INJURY</b><br><input checked="" type="checkbox"/> 365 Personal Injury - Product Liability<br><input type="checkbox"/> 367 Health Care/Pharmaceutical Personal Injury Product Liability<br><input type="checkbox"/> 368 Asbestos Personal Injury Product Liability<br><b>PERSONAL PROPERTY</b><br><input type="checkbox"/> 370 Other Fraud<br><input type="checkbox"/> 371 Truth in Lending<br><input type="checkbox"/> 380 Other Personal Property Damage<br><input type="checkbox"/> 385 Property Damage Product Liability | <input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881<br><input type="checkbox"/> 690 Other<br><b>LABOR</b><br><input type="checkbox"/> 710 Fair Labor Standards Act<br><input type="checkbox"/> 720 Labor/Management Relations<br><input type="checkbox"/> 740 Railway Labor Act<br><input type="checkbox"/> 751 Family and Medical Leave Act<br><input type="checkbox"/> 790 Other Labor Litigation<br><input type="checkbox"/> 791 Employee Retirement Income Security Act<br><b>IMMIGRATION</b><br><input type="checkbox"/> 462 Naturalization Application<br><input type="checkbox"/> 465 Other Immigration Actions | <input type="checkbox"/> 422 Appeal 28 USC 158<br><input type="checkbox"/> 423 Withdrawal 28 USC 157<br><b>INTELLECTUAL PROPERTY RIGHTS</b><br><input type="checkbox"/> 820 Copyrights<br><input type="checkbox"/> 830 Patent<br><input type="checkbox"/> 835 Patent - Abbreviated New Drug Application<br><input type="checkbox"/> 840 Trademark<br><input type="checkbox"/> 880 Defend Trade Secrets Act of 2016<br><b>SOCIAL SECURITY</b><br><input type="checkbox"/> 861 HIA (1395ff)<br><input type="checkbox"/> 862 Black Lung (923)<br><input type="checkbox"/> 863 DIWC/DIWW (405(g))<br><input type="checkbox"/> 864 SSID Title XVI<br><input type="checkbox"/> 865 RSI (405(g))<br><b>FEDERAL TAX SUITS</b><br><input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant)<br><input type="checkbox"/> 871 IRS—Third Party 26 USC 7609 | <input type="checkbox"/> 375 False Claims Act<br><input type="checkbox"/> 376 Qui Tam (31 USC 3729(a))<br><input type="checkbox"/> 400 State Reapportionment<br><input type="checkbox"/> 410 Antitrust<br><input type="checkbox"/> 430 Banks and Banking<br><input type="checkbox"/> 450 Commerce<br><input type="checkbox"/> 460 Deportation<br><input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations<br><input type="checkbox"/> 480 Consumer Credit (15 USC 1681 or 1692)<br><input type="checkbox"/> 485 Telephone Consumer Protection Act<br><input type="checkbox"/> 490 Cable/Sat TV<br><input type="checkbox"/> 850 Securities/Commodities/Exchange<br><input type="checkbox"/> 890 Other Statutory Actions<br><input type="checkbox"/> 891 Agricultural Acts<br><input type="checkbox"/> 893 Environmental Matters<br><input type="checkbox"/> 895 Freedom of Information Act<br><input type="checkbox"/> 896 Arbitration<br><input type="checkbox"/> 899 Administrative Procedure Act/Review or Appeal of Agency Decision<br><input type="checkbox"/> 950 Constitutionality of State Statutes |
| <b>REAL PROPERTY</b><br><input type="checkbox"/> 210 Land Condemnation<br><input type="checkbox"/> 220 Foreclosure<br><input type="checkbox"/> 230 Rent Lease & Ejectment<br><input type="checkbox"/> 240 Torts to Land<br><input type="checkbox"/> 245 Tort Product Liability<br><input type="checkbox"/> 290 All Other Real Property                                                                                                                                                                                                                                                                                                                                                      | <b>CIVIL RIGHTS</b><br><input type="checkbox"/> 440 Other Civil Rights<br><input type="checkbox"/> 441 Voting<br><input type="checkbox"/> 442 Employment<br><input type="checkbox"/> 443 Housing/Accommodations<br><input type="checkbox"/> 445 Amer. w/Disabilities - Employment<br><input type="checkbox"/> 446 Amer. w/Disabilities - Other<br><input type="checkbox"/> 448 Education<br><b>PRISONER PETITIONS</b><br><b>Habeas Corpus:</b><br><input type="checkbox"/> 463 Alien Detainee<br><input type="checkbox"/> 510 Motions to Vacate Sentence<br><input type="checkbox"/> 530 General<br><input type="checkbox"/> 535 Death Penalty<br><b>Other:</b><br><input type="checkbox"/> 540 Mandamus & Other<br><input type="checkbox"/> 550 Civil Rights<br><input type="checkbox"/> 555 Prison Condition<br><input type="checkbox"/> 560 Civil Detainee - Conditions of Confinement                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

**V. ORIGIN** (Place an "X" in One Box Only)

- ☒ 1 Original Proceeding ☐ 2 Removed from State Court ☐ 3 Remanded from Appellate Court ☐ 4 Reinstated or Reopened ☐ 5 Transferred from Another District (specify) ☐ 6 Multidistrict Litigation - Transfer ☐ 8 Multidistrict Litigation - Direct File

**VI. CAUSE OF ACTION**

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):  
28 U.S.C. 1332

Brief description of cause:  
Product Liability, Negligence, WPLA

**VII. REQUESTED IN COMPLAINT:**

☐ CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P.

DEMAND \$

CHECK YES only if demanded in complaint:

JURY DEMAND: ☒ Yes ☐ No

**VIII. RELATED CASE(S) IF ANY**

(See instructions):

JUDGE \_\_\_\_\_ DOCKET NUMBER \_\_\_\_\_

DATE

06/05/2026

SIGNATURE OF ATTORNEY OF RECORD

/s/ David J. Ko

**FOR OFFICE USE ONLY**

RECEIPT # \_\_\_\_\_ AMOUNT \_\_\_\_\_ APPLYING IFP \_\_\_\_\_ JUDGE \_\_\_\_\_ MAG. JUDGE \_\_\_\_\_

**INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44**

## Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I.(a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
  - (b) County of Residence.** For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
  - (c) Attorneys.** Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- II. Jurisdiction.** The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.
- United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here. United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.
- Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.
- Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)
- III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- IV. Nature of Suit.** Place an "X" in the appropriate box. If there are multiple nature of suit codes associated with the case, pick the nature of suit code that is most applicable. Click here for: [Nature of Suit Code Descriptions](#).
- V. Origin.** Place an "X" in one of the seven boxes.
- Original Proceedings. (1) Cases which originate in the United States district courts.
- Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441.
- Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.
- Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.
- Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.
- Multidistrict Litigation – Transfer. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407.
- Multidistrict Litigation – Direct File. (8) Check this box when a multidistrict case is filed in the same district as the Master MDL docket.
- PLEASE NOTE THAT THERE IS NOT AN ORIGIN CODE 7.** Origin Code 7 was used for historical records and is no longer relevant due to changes in statute.
- VI. Cause of Action.** Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service.
- VII. Requested in Complaint.** Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.
- Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction.
- Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases.** This section of the JS 44 is used to reference related cases, if any. If there are related cases, insert the docket numbers and the corresponding judge names for such cases.

**Date and Attorney Signature.** Date and sign the civil cover sheet.

AO 440 (Rev. 06/12) Summons in a Civil Action

## UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

\_\_\_\_\_  
*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

\_\_\_\_\_  
*Defendant(s)*

Civil Action No.

## SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Olympus America Inc.  
c/o Corporation Services Company  
2595 Interstate Dr #103  
Harrisburg, PA 17110

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_ .

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_ , a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_ , and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_ , who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I returned the summons unexecuted because \_\_\_\_\_ ; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ \_\_\_\_\_ 0.00 .

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc:

AO 440 (Rev. 06/12) Summons in a Civil Action

# UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

*Defendant(s)*

Civil Action No.

## SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Olympus Corporation  
2951 Ishikawa-maschi, Hachioji-shi  
Tokyo 192-8507, Japan

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_.

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_, a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_, who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_; or

☐ I returned the summons unexecuted because \_\_\_\_\_; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ 0.00.

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc:

AO 440 (Rev. 06/12) Summons in a Civil Action

## UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

\_\_\_\_\_  
*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

\_\_\_\_\_  
*Defendant(s)*

Civil Action No.

## SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Olympus Medical Systems Corp.  
2951 Ishikawa-maschi  
Hachioji-shi, Tokyo 192-8507, Japan

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_ .

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_, a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_, who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I returned the summons unexecuted because \_\_\_\_\_ ; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ 0.00 .

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc:

AO 440 (Rev. 06/12) Summons in a Civil Action

## UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

\_\_\_\_\_  
*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

\_\_\_\_\_  
*Defendant(s)*

Civil Action No.

## SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Olympus Corporation of the Americas  
3500 Corporate Parkway  
Center Valley, PA 18034

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_.

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_, a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_, who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_; or

☐ I returned the summons unexecuted because \_\_\_\_\_; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ 0.00.

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc:

AO 440 (Rev. 06/12) Summons in a Civil Action

---

---

UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

---

*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

---

*Defendant(s)*

Civil Action No.

**SUMMONS IN A CIVIL ACTION**

To: *(Defendant's name and address)* Olympus Surgical Technologies America  
800 West Park Drive  
Westborough, Massachusetts, 01581

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_ .

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_, a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_, who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I returned the summons unexecuted because \_\_\_\_\_ ; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ 0.00 .

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc:

## UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

\_\_\_\_\_  
*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

\_\_\_\_\_  
*Defendant(s)*

Civil Action No.

## SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Aizu Olympus Co.  
3-1 Nishi-Shinjuku 2-Chome Shinjuku-Ku  
Tokyo 163-0914 Japan

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_ .

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_ , a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_ , and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_ , who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I returned the summons unexecuted because \_\_\_\_\_ ; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ \_\_\_\_\_ 0.00 .

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc:

AO 440 (Rev. 06/12) Summons in a Civil Action

# UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

*Defendant(s)*

Civil Action No.

## SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Aomori Olympus Co. Ltd  
2-248-1 Okkonoki, Kuroishi-shi,  
Aomori 036-0357, Japan

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_ .

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_, a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_, who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I returned the summons unexecuted because \_\_\_\_\_ ; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ 0.00 .

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc:

## UNITED STATES DISTRICT COURT

for the

Western District of Washington

MICHELLE BRUTO DA COSTA, Individually and as  
personal representative of the Estate of MARK  
BRUTO DA COSTA, deceased,

\_\_\_\_\_  
*Plaintiff(s)*

v.

OLYMPUS AMERICA INC., OLYMPUS CORPORATION,  
OLYMPUS MEDICAL SYSTEMS CORP., OLYMPUS  
CORPORATION OF THE AMERICAS, OLYMPUS SURGICAL  
TECHNOLOGIES AMERICA, AIZU OLYMPUS CO. LTD, AOMORI  
OLYMPUS CO. LTD., SHIRAKAWA OLYMPUS CO. LTD.,

\_\_\_\_\_  
*Defendant(s)*

Civil Action No.

## SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Shirakawa Olympus Co. Ltd  
3-1 Oaza-Odakura-Aza-Okamiyama,  
Nishigo-mura, Nishishirakawa-gun,  
Fukushima 961-8061, Japan

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

David J. Ko  
Keller Rohrback L.L.P.  
1201 Third Avenue, Suite 3400  
Seattle, WA 98101

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: \_\_\_\_\_

\_\_\_\_\_  
*Signature of Clerk or Deputy Clerk*

Civil Action No. \_\_\_\_\_

**PROOF OF SERVICE***(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))*

This summons for *(name of individual and title, if any)* \_\_\_\_\_  
 was received by me on *(date)* \_\_\_\_\_ .

☐ I personally served the summons on the individual at *(place)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* \_\_\_\_\_  
 \_\_\_\_\_, a person of suitable age and discretion who resides there,  
 on *(date)* \_\_\_\_\_, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* \_\_\_\_\_, who is  
 designated by law to accept service of process on behalf of *(name of organization)* \_\_\_\_\_  
 \_\_\_\_\_ on *(date)* \_\_\_\_\_ ; or

☐ I returned the summons unexecuted because \_\_\_\_\_ ; or

☐ Other *(specify)*: \_\_\_\_\_

My fees are \$ \_\_\_\_\_ for travel and \$ \_\_\_\_\_ for services, for a total of \$ \_\_\_\_\_ 0.00 .

I declare under penalty of perjury that this information is true.

Date: \_\_\_\_\_

\_\_\_\_\_  
*Server's signature*

\_\_\_\_\_  
*Printed name and title*

\_\_\_\_\_  
*Server's address*

Additional information regarding attempted service, etc: